rabbit anti il 15 polyclonal antibody  (Sino Biological)

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer

doi: 10.1073/pnas.2306782120

Figure Lengend Snippet: Endogenous IL-15 participates in the therapeutic activity of CD40 agonism. ( A ) Schematic of the treatment of mice bearing orthotopic MB49 bladder tumors with anti-CD40 antibody and/or anti-IL-15 blocking antibody or isotype-matched control antibody. ( B ) Representative intravital luciferase imaging ( Left ) and quantification of luminescence ( Center ) and bladder weights ( Right ) across mice at day 12 post-tumor implantation (n = 5 mice per group; bars represent SD). ( C ) Representative flow cytometry plots and quantification across mice (n = 5 mice per group) of CD44 hi CD122 + CD8 T cells ( Top ) and CXCR6 + CD44 hi CD122 + CD8 T cells ( Bottom ) in the bladders of mice treated as outlined in A . * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

Article Snippet: Surface IL-15 was stained with biotinylated anti-mouse IL-15 (polyclonal rabbit; PeproTech) followed by streptavidin-APC (R&D).

Techniques: Activity Assay, Blocking Assay, Luciferase, Imaging, Tumor Implantation, Flow Cytometry

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer

doi: 10.1073/pnas.2306782120

Figure Lengend Snippet: CD40 agonism induces IL-15/IL-15Rα upregulation on DCs in the bladder tumor microenvironment. Mice bearing orthotopic MB49 bladder tumors were treated intravesically with anti-CD40 antibody, BCG, or isotype-matched control antibody on days 6 and 9 post-tumor implantation. ( A ) Representative histogram and ( B ) quantification across mice of IL-15Rα mean fluorescence intensity on type-1 conventional DCs (cDC1; defined as F4/80 − Ly-6G − CD11c + MHCII + XCR1 + ), type-2 conventional DCs (cDC2; defined as F4/80 − Ly-6G − CD11c + MHCII + SIRPα + ), macrophages (defined as CD11b + F4/80 + Ly-6G − ), and neutrophils (defined as CD11b + Ly-6G + ) in the bladder microenvironment as assessed by flow cytometry at day 12 post-tumor implantation (n = 5 mice per group). ( C ) Representative flow cytometry plots and ( D ) quantification across mice of IL-15 and IL-15Rα surface expression on cDC1s in the bladder microenvironment as assessed by flow cytometry at day 12 post-tumor implantation (n = 5 mice per group). The left graph is gated on cDC1s and depicts proportions of cDC1s that are double-positive for surface IL-15 and IL-15Rα. The right graph is gated on IL-15Rα-expressing cDC1s and depicts proportions of cDC1s expressing IL-15Rα that is occupied by IL-15. ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

Article Snippet: Surface IL-15 was stained with biotinylated anti-mouse IL-15 (polyclonal rabbit; PeproTech) followed by streptavidin-APC (R&D).

Techniques: Tumor Implantation, Fluorescence, Flow Cytometry, Expressing